Loomis Sayles & Co. L P Buys 393,997 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Loomis Sayles & Co. L P grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 33.4% during the 4th quarter, Holdings Channel reports. The firm owned 1,575,349 shares of the biopharmaceutical company’s stock after purchasing an additional 393,997 shares during the period. Regeneron Pharmaceuticals makes up approximately 121.2% of Loomis Sayles & Co. L P’s portfolio, making the stock its 17th biggest position. Loomis Sayles & Co. L P’s holdings in Regeneron Pharmaceuticals were worth $1,122,168,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Amundi grew its position in shares of Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock valued at $1,138,074,000 after acquiring an additional 487,489 shares during the period. Proficio Capital Partners LLC increased its stake in shares of Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock valued at $156,284,000 after buying an additional 219,162 shares during the period. Worldquant Millennium Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter worth about $127,489,000. Thrivent Financial for Lutherans raised its stake in Regeneron Pharmaceuticals by 1,272.7% during the fourth quarter. Thrivent Financial for Lutherans now owns 125,194 shares of the biopharmaceutical company’s stock worth $89,179,000 after buying an additional 116,074 shares during the last quarter. Finally, KBC Group NV boosted its holdings in shares of Regeneron Pharmaceuticals by 296.7% during the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock worth $97,338,000 after buying an additional 102,198 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the subject of several recent research reports. Citigroup decreased their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday, February 4th. Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Sanford C. Bernstein lowered their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Finally, Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Up 0.9 %

Shares of Regeneron Pharmaceuticals stock opened at $640.14 on Thursday. The company has a market capitalization of $69.98 billion, a P/E ratio of 16.72, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 1 year low of $629.02 and a 1 year high of $1,211.20. The business has a 50-day moving average of $685.91 and a two-hundred day moving average of $805.04.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $11.86 EPS. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.55%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.